Blend
Cagrilintide + Semaglutide
Size
Research Profile
Cagrilintide + Semaglutide
Literature-based research context for laboratory reference only.
CagriSema combines an amylin analogue with a GLP-1 agonist. Research examines the complementary satiety mechanisms — central amylin receptor activation and peripheral GLP-1 receptor activation — for additive effects on body weight and glycemic control.
Selected literature
- Enebo et al., 2021, Lancet.
This page is provided for laboratory reference and literature review only. The material is not presented as a consumer product, medical treatment, diagnostic tool, or recommendation for human or animal use.
Overview
Cagrilintide + Semaglutide is presented here as a laboratory reference entry. The Research Profile summarizes literature-based biological context, while this Overview documents the identity record, specification set, preparation format, and quality-reference information available on the page.
The identity block lists a blend identity rather than a single CAS number, molecular formula Blend, and molecular weight Blend. The material record is paired with ≥99% purity information and a lyophilized presentation for reference review.
Available specification labels include 10mg（5mg/5mg）. The active selection is 10mg（5mg/5mg）; changing the selector updates the visible specification label and COA lot references while preserving the same research-reference context.
For the active selection, the page currently shows 1 active COA lot reference. COA links, when present, are retained for batch-level purity, identity, and quantity review, while packaging and storage details remain separated in Structure & Identity.